北京阳光诺和药物研究股份有限公司 2024 年第二次临时股东大会会议资料 证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 2024 年第二次临时股东大会会议资料 二〇二四年九月 北京阳光诺和药物研究股份有限公司 2024 年第二次临时股东大会会议资料 北京阳光诺和药物研究股份有限公司 2024 年第二次临时股东大会会议资料目录 | 2024 | 年第二次临时股东大会会议须知 | 3 | | --- | --- | --- | | 2024 | 年第二次临时股东大会会议议程 | 6 | | | 议案一：关于提名公司非独立董事候选人的议案 | 8 | 北京阳光诺和药物研究股份有限公司 2024 年第二次临时股东大会会议资料 北京阳光诺和药物研究股份有限公司 3 北京阳光诺和药物研究股份有限公司 2024 年第二次临时股东大会会议资料 五、股东及股东代理人要求在股东大会现场会议上发言的，应于股东大会召 开前一天向大会会务组进行登记。大会主持人根据会务组提供的名单和顺序安排 发言。 2024 年第二次临时股东大会会议须知 为维护全体股东的合法利益，确保股东大会的正常秩序和议事效率，保证大 ...

Group 1: Company Overview - The company is Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd., listed under stock code 688621 [1] - The company focuses on the research and development of innovative drugs, particularly peptide and small nucleic acid drugs [3][4] Group 2: Research and Development - The company has over 10 innovative drugs in development, with "STC007 injection" currently in Phase II clinical trials targeting moderate to severe itching in adult chronic kidney disease patients [4][7] - R&D efficiency is on the rise, with a laboratory area of 37,900 square meters and a capacity utilization rate exceeding 80% [4][5] - The R&D team has expanded to 1,163 members, accounting for 83.43% of total employees, with a per capita output value of 407,300 yuan [4][5] Group 3: Financial Performance - In the first half of 2024, the company achieved revenue of 562.86 million yuan, a year-on-year increase of 22.08%, and a net profit attributable to shareholders of 148.57 million yuan, up 25.91% [8][9] - Revenue from clinical trials and bioanalysis services reached 216.55 million yuan, a growth of 50.28% compared to the previous year [5][6] Group 4: Client Base and Market Position - The company serves nearly 900 pharmaceutical enterprises, with 80% being large domestic pharmaceutical companies, ensuring stable cash flow and product pipeline needs [6][9] - The company has established a strong reputation and customer loyalty, which supports future business growth [9][10] Group 5: Strategic Response to Market Changes - The company maintains a cautious approach to the generic drug procurement policy, viewing it as a positive signal for price reduction and drug accessibility [10] - The company is committed to optimizing cost structures and improving R&D efficiency to remain competitive under the procurement policy [10]

主业快速增长，自研品种不断推进 [Table_Industry] [Table_Title] 评级：买入(维持) 市场价格：30.88 元 [Table_Finance] 公司盈利预测及估值 指标 2022A 2023A 2024E 2025E 2026E 营业收入（百万元） 676.61 932.12 1197.90 1492.91 1878.87 增长率 yoy% 37.06% 37.76% 28.51% 24.63% 25.85% 净利润（百万元） 156.47 184.76 240.76 303.32 397.01 增长率 yoy% 48.09% 18.08% 30.31% 25.98% 30.89% 每股收益（元） 1.40 1.65 2.15 2.71 3.54 每股现金流量 0.93 0.83 1.89 1.61 2.43 净资产收益率 17.45% 17.76% 19.07% 19.89% 21.14% P/E 22.10 18.72 14.37 11.40 8.71 PEG 0.46 1.04 0.47 0.44 0.28 P/B 3.86 3.33 2.74 2.27 1.84 备注：截止 ...

证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|----------------------------------------------| | | | | | | R | 特定对象调研 £分析师会议 | | 投资者关系活动 | □ 媒体采访 £业绩说明会 | | | | □新闻发布会 □路演活动 | | | 类别 | £ 现场参观 | | | | £ 其他（电话会议） | | | 参与单位名称 | 建信基金、东吴证券 | | | 时间 | 2024 年 9 月 5 日 | | | 参会方式 | 线上会议 | | | 上市公司接待人 | | | | 员姓名 | 证券事务代表：魏丽萍女士 | | | 投资者关系活动 | 一、公司介绍环节 | | | 主要内容介绍 | | 公司是一家专业的药物临床前及临床综合研发服务 | （2024 年 9 月） | --- | |------------------------------- ...

%% %% 丨证券研究报告丨 公司研究丨点评报告丨阳光诺和（688621.SH） [Table_Title] 2024H1 财报点评：临床高增，权益分成未来可 期 | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | 年半年度报告， 2024 年上半年实现营业收入 5.63 亿元，同比增长 22.08% ； 1.49 亿元，同比增长 25.91% ；实现扣非归母净利润 1.43 亿元，同比增长 。得益于公司 ...

证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|----------------------------------------------| | | | | | | R | 特定对象调研 £分析师会议 | | 投资者关系活动 | □ 媒体采访 £业绩说明会 | | | | □新闻发布会 □路演活动 | | | 类别 | £ 现场参观 | | | | £ 其他（电话会议） | | | 参与单位名称 | | 华泰保险资产、国海富兰克林、国海证券 | | 时间 | 2024 年 9 月 2 日 | | | 参会方式 | 线上会议 | | | 上市公司接待人 | 董事长：利虔先生 | | | 员姓名 | 证券事务代表：魏丽萍女士 | | | 投资者关系活动 | 一、公司介绍环节 | | | 主要内容介绍 | | 公司是一家专业的药物临床前及临床综合研发服务 | （2024 年 9 月） | --- | |------------- ...

证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|-------------------------|--------------------------|--------------------------------------------------| | | | | | | | R | 特定对象调研 £分析师会议 | | | 投资者关系活动 | □ 媒体采访 £业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | 类别 | £ 现场参观 | | | | | £ 其他（电话会议） | | | | | | | 广发证券、民生证券、中银证券、长江证券、兴业证 | | | | | 券、开源证券、浙商证券、国盛证券、东吴证券、光大 | | 参与单位名称 | | | 证券、招商证券、海通证券、华西证券、德邦证券、太 | | | | | 平洋证券、东北证券、华安证券、国金证券、华创证 | | | 券、信达证券 | | | | 时间 | 2024 年 8 月 3 ...

证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|----------------------------------------------| | | | | | | R | 特定对象调研 £分析师会议 | | 投资者关系活动 | □ 媒体采访 £业绩说明会 | | | | □新闻发布会 □路演活动 | | | 类别 | £ 现场参观 | | | | £ 其他（电话会议） | | | 参与单位名称 | | 华泰保险资产、国海富兰克林、国海证券 | | 时间 | 2024 年 9 月 2 日 | | | 参会方式 | 线上会议 | | | 上市公司接待人 | 董事长：利虔先生 | | | 员姓名 | 证券事务代表：魏丽萍女士 | | | 投资者关系活动 | 一、公司介绍环节 | | | 主要内容介绍 | | 公司是一家专业的药物临床前及临床综合研发服务 | （2024 年 9 月） | --- | |------------- ...

证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|-------------------------|--------------------------|--------------------------------------------------| | | | | | | | R | 特定对象调研 £分析师会议 | | | 投资者关系活动 | □ 媒体采访 £业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | 类别 | £ 现场参观 | | | | | £ 其他（电话会议） | | | | | | | 广发证券、民生证券、中银证券、长江证券、兴业证 | | | | | 券、开源证券、浙商证券、国盛证券、东吴证券、光大 | | 参与单位名称 | | | 证券、招商证券、海通证券、华西证券、德邦证券、太 | | | | | 平洋证券、东北证券、华安证券、国金证券、华创证 | | | 券、信达证券 | | | | 时间 | 2024 年 8 月 3 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown robust performance in the first half of 2024, with a revenue of 563 million yuan, representing a year-on-year growth of 22.08%, and a net profit attributable to shareholders of 149 million yuan, up 25.91% year-on-year [4] - The company is expected to maintain strong growth due to abundant orders and rapid development in clinical services, with projected net profits for 2024-2026 at 274 million, 363 million, and 472 million yuan respectively [4] Financial Performance Summary - In H1 2024, the company achieved a revenue of 563 million yuan, a 22.08% increase year-on-year; net profit attributable to shareholders was 149 million yuan, a 25.91% increase year-on-year; and non-recurring net profit was 143 million yuan, up 24.49% year-on-year [4] - For Q2 2024, the company reported a revenue of 311 million yuan, a 35.86% increase year-on-year and a 23.12% increase quarter-on-quarter; net profit attributable to shareholders was 75.82 million yuan, an 8.22% increase year-on-year and a 4.21% increase quarter-on-quarter [4] - The company’s revenue from the pharmaceutical research business in H1 2024 was 343 million yuan, an 8.29% increase year-on-year [5] - The clinical trial and bioanalysis services generated revenue of 217 million yuan in H1 2024, reflecting a 50.28% year-on-year growth [6] Project and Development Highlights - As of June 2024, the company has initiated 117 new self-research projects, with a total of over 450 projects; 8 new drug projects have entered clinical trials, and 70 drug applications have been accepted for market registration [5] - The company is focusing on the development of peptide and small nucleic acid drugs, with ongoing clinical trials for "STC007 injection" and "STC008 injection" [5] Financial Forecasts - The company’s projected revenues for 2024-2026 are 1.198 billion, 1.546 billion, and 2.008 billion yuan respectively, with year-on-year growth rates of 28.5%, 29.1%, and 29.8% [7] - The projected net profits for the same period are 274 million, 363 million, and 472 million yuan, with year-on-year growth rates of 48.2%, 32.6%, and 30.0% [7] - The company’s earnings per share (EPS) are expected to be 2.44, 3.24, and 4.21 yuan for 2024, 2025, and 2026 respectively [7]